Compare US Global Jets ETF (JETS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Novartis AG — how do they compare? US Global Jets ETF trades at $31.77, while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while US Global Jets ETF pays none, and US Global Jets ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| JETS | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $168.62 |
52-Week Low | $23.51 | $118.55 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $32.54, down 0.31% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent news highlights mixed sentiment, including JetBlue's earnings beat lifting airline stocks but fuel cost pressures and geopolitical risks weighing on the sector. The ETF faces volatility from oil price swings and competitive ETF comparisons.
Outlook is cautious due to high sensitivity to fuel costs and travel demand cycles. Opportunities exist if oil remains low, but risks from Middle East tensions and economic slowdowns could pressure earnings. Investors should weigh JETS' cyclical nature against broader aerospace ETFs for diversification.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
